Effect of liposome bupivacaine on quality QoR-15 recovery after laparoscopic gastrectomy for ultrasound-guided subcostal transversal muscle plane block

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094184

Enrollment

Unknown

Registered

2024-12-18

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Liposome bupivacaine group: Liposome bupivacaine 10ml was diluted to 30ml with 0.9% normal saline, 15ml on each side

Bupivacaine hydrochloride group:10ml bupivacaine hydrochloride diluted to 30ml with 0.9% normal saline, 15ml on each side

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. In accordance with the diagnostic criteria of Gastric Cancer in the Diagnostic Criteria for Gastric Cancer, the diagnosis of gastric cancer was confirmed by imaging and pathological examination; 2. Age 18-75 years old; 3.ASA: Level II-III; 4. Sign informed consent;

Exclusion criteria

Exclusion criteria: 1. Allergic to the drug used in the test; 2. Severe cardiac, liver and renal insufficiency; 3. Combined with abnormal coagulation function; 4. Block site infection;

Design outcomes

Primary

Measure	Time frame
Postoperative recovery quality;	—

Countries

China

Contacts

Public ContactWenmei Xu

Xichang City People's Hospital

17781085082@163.com+86 177 8108 5082

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026